F6pzln34sj67rfzntnpd remynd

reMYND

Leuven (Heverlee), BE

reMYND drives the development of disease-modifying treatments against protein misfolding disorders

reMYND NV, founded in 2002 as a spin-off from the University of Leuven, drives the development of disease-modifying treatments against Alzheimer’s, Parkinson’s, Diabetes and other orphan protein misfolding disorders. reMYND is organized along two independently managed business units, the Contract Research Organization (CRO) and the own Drug Discovery & Development unit:

Contract Research

The in-vivo Contract Research Organization (CRO) helps its clients assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease in reMYND’s proprietary Alzheimer mouse models. Its mission is to be a strategic partner for its clients and help them identify the most promising set-up to assess potential effects.

*In vivo efficacy testing of experimental Alzheimer treatments in... Show more »

reMYND drives the development of disease-modifying treatments against protein misfolding disorders

reMYND NV, founded in 2002 as a spin-off from the University of Leuven, drives the development of disease-modifying treatments against Alzheimer’s, Parkinson’s, Diabetes and other orphan protein misfolding disorders. reMYND is organized along two independently managed business units, the Contract Research Organization (CRO) and the own Drug Discovery & Development unit:

Contract Research

The in-vivo Contract Research Organization (CRO) helps its clients assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease in reMYND’s proprietary Alzheimer mouse models. Its mission is to be a strategic partner for its clients and help them identify the most promising set-up to assess potential effects.

In vivo efficacy testing of experimental Alzheimer treatments in extensively validated transgenic mouse models

Given the extensive experience fully focused on Alzheimer's, reMYND’s CRO can contribute its expertise for every type of Alzheimer treatment in any form of application.

reMYND, a trusted research partner

reMYND’s Contract Research Organization (CRO) is a trusted research partner specialized in the pre-clinical in vivo testing of all experimental Alzheimer treatments. By contributing our extensive expertise and experience we are helping our clients in understanding as fast as possible the therapeutic in vivo effects of their lead preclinical Alzheimer therapies.

  • World-class CRO with clients in US, Europe and Japan, including the leading biotechs and a majority of the top 10 pharmaco’s
  • Research partner in the preclinical in-vivo testing of all types of Alzheimer treatments
    • testing of tau and Abeta directed approaches, as well as other hypotheses
    • small molecule and immunization strategies;
    • prophylactic and curative treatments;
    • pharmaceuticals and nutraceuticals;
  • Mastering all routes of administration (e.g., gavage, stereotactic injection in brain, ip, sc, iv)
  • Offering a set of proprietary unique and validated mouse models
    • based on the human clinical APP-London allele APP[V717I] either alone or in combination with the human clinical PS1[A246E] allele
    • based on the human clinical TAU[P301L] allele – featuring a progressive tauopathy model – extended to an APPxTAU model, combining both amyloid and tau pathology
    • now adding TAU[P301S] as a complementary tauopathy model
  • With a broad testing window for a whole portfolio of behavioral, immunohistochemical and biochemical read-outs, both in brain and csf
  • Committed to a short response time allowing rapid study start also with aged mice
  • High client satisfaction is our key driver, committing us to excel in communication, dedication and flexibility.

The CRO is serving 6 of the Top 10 pharmaco’s worldwide and its client-base covers the US, Europe and Japan. The CRO has provided in-vivo proof-of-concept data for several candidate drugs that reMYND’s clients have currently in clinical development.

Drug discovery

reMYND’s own Drug Discovery & Development unit focuses entirely on disease-modifying treatments with the aim to decelerate – or even reverse – cellular degeneration found in protein misfolding disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), type 2 diabetes mellitus (T2DM) and several orphan diseases.

As such, reMYND responds to a clear unmet medical need, as all marketed treatments and the majority of the products under development world-wide are aimed mainly to mitigate symptoms.
reMYND’s pipeline primarily consists of 4 disease-modifying programs counteracting tau-toxicity for AD, 2 programs for T2DM, and 2 counteracting synuclein-toxicity for PD, with recent additions in orphan diseases.

« Show less

reMYND has not listed any services.

Drug Discovery & Development
Price on request

reMYND's Drug Discovery & Development focuses entirely on disease-modifying treatments with the aim to decelerate – or even stop – cellular degeneration in patients suffering protein misfolding disorders, such as Alzheimer's and Parkinson's disease. As such, reMYND responds to a clear unmet medical need, as all... Show more »

reMYND's Drug Discovery & Development focuses entirely on disease-modifying treatments with the aim to decelerate – or even stop – cellular degeneration in patients suffering protein misfolding disorders, such as Alzheimer's and Parkinson's disease. As such, reMYND responds to a clear unmet medical need, as all marketed treatments and the majority of the products under development world-wide are aimed to only mitigate symptoms in the respective disorders.

Alzheimer's disease

It is estimated that there are currently 26 million people worldwide with Alzheimer’s disease. This number is expected to reach 100 million by 2050. Existing therapies are all symptomatic, whereas most ongoing developments for 'causal' remedies aimed to inhibit neuronal degeneration have failed up to now.

Parkinson's disease

Parkinson’s disease is the most common motor disorder, typically affecting the aged (65+) population. About 0.1% to 0.2% of the western population is a Parkinson’s patient. It is expected that the number of patients suffering from Parkinson’s disease will double in the next ten years, reflecting the aging of the population in the western world. With the exception of cell transplants and gene therapy programs there are have been no breakthroughs in the field since the seventies.

Diabetes mellitus type 2

Diabetes mellitus type 2 is a chronic metabolic disorder resulting from a failure to manage glucose levels in the blood appropriately. The 2008 prevalence of diabetes mellitus in the seven major markets was 8.5% (about 10 times higher than the 0.9% prevalence of Alzheimer’s disease, and 40 times higher than Parkinson’s). The major increase however will happen in Asia and the Rest-of-World, resulting in an estimated global number of diabetics of 380 million people worldwide in 2025, an increase of over 50% in less than 20 years.

Other protein misfolding disorders

reMYND’s technology platform is amenable to address numerous other, highly delibiting protein-misfolding disorders, such as Huntington’s disease or Amyotrophic Lateral Sclerosis, to discover and develop drug candidates. A further diversification of our product pipeline comprising other protein misfolding disorders is anticipated in the near future.

« Show less
Alzheimer's Disease Animal Models
Price on request
Request a quote for more information about this service.
Animal Models and Studies
Price on request
Request a quote for more information about this service.
Animal Models of Disease
Price on request
Request a quote for more information about this service.
CNS/Neurology Animal Models
Price on request
Request a quote for more information about this service.

reMYND has not received any ratings.

Be the first to endorse reMYND

Endorse this lab